Ivonescimab -- a novel first-in-class PD-1/VEGF bispecific antibody -- led to clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) as first ...

These categories included patients whose tumours had PD-L1 tumour proportion scores (TPS) of 1-49% - a patient group that does not often respond well to checkpoint inhibitor monotherapy.

TPS: a biomarker used to measure the percentage of tumor cells expressing PD-L1. TPS greater than 1% indicates low expression of PD-L1, TPS 1 to 49% indicates moderate expression, and TPS greater than ...

Onc.AI, a digital health company developing advanced AI-driven clinical management solutions for oncology, today announced that findings from a recent collaboration with global biopharma company GSK ...

Jemperli performed better than Keytruda on some measures – such as tumours which express PD-L1 at levels between 1% and 49% and tumour proportion scores (TPS) above 50% – but Merck’s drug ...

Solnerstotug showed a 14% response rate and 62% disease control in PD-L1 resistant tumors, surpassing typical expectations. Significant responses were observed in Merkel cell carcinoma and ...

The research reveals a strong correlation between AI-driven PD-L1 intensity scores and clinically assessed Tumor Proportion Scores (TPS), underscoring the potential of AI in enhancing precision ...